At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 71 enrolled
Drug / intervention
Everolimusdrug
Likely dose
Everolimus 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Triple-arm, Single-stage, Phase II Trial to Determine the Preliminary Efficacy and Safety of RAD001 in Patients With Histological Evidence of Progressive or Metastatic Bone or Soft Tissue Sarcomas
In Brief
A Phase 2 clinical trial evaluating Everolimus for Progressive Sarcoma. Completed, enrolled 71 participants across 6 sites in 2 countries.
Detailed Summary
The purpose of this multicenter, three-arm, exact binomial single-stage, phase II trial is to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tissue sarcoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProgressive Sarcoma
CountriesGermany, Italy
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedOct 2008
Primary CompletionMay 2017
TodayJul 2026
First PostedOct 7, 2008
Enrollment StartMar 31, 2008
Primary CompletionMay 17, 2017
TodayJul 2, 2026
Enrollment to primary: 9.1 yearsPosted 17.7 years ago
Interventions
Everolimusdrug
2.5 and 5 mg tablets taken orally and starting dose was 10 mg daily for all patients